CD274 and neoplasm: For the approved anti-PD-1 blockers, several tumor biomarkers have been proposed, with variable level of clinical validation on large cohorts of patients and different cancers: PD-L1 staining (on tumor cells or both tumor and immune cells) evaluated by immunohistochemistry IHC, TMB, and the microsatellite instability (MSI) status, the infiltration of CD8 T cells, some transcriptomic signatures as TIS (Tumor Inflammation Signature) and TIDE (Tumor Immune Dysfunction and Exclusion), the presence of B cells and tertiary lymphoid structures, as reported elsewhere (9–11, 28–30).